Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Accumulated Expenses: 2021-2024

Historic Accumulated Expenses for ARS Pharmaceuticals (SPRY) over the last 2 years, with Dec 2024 value amounting to $2.3 million.

  • ARS Pharmaceuticals' Accumulated Expenses was N/A to $11.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.3 million, marking a year-over-year change of. This contributed to the annual value of $2.3 million for FY2024, which is N/A change from last year.
  • According to the latest figures from FY2024, ARS Pharmaceuticals' Accumulated Expenses is $2.3 million, which was down 80.45% from $11.7 million recorded in FY2021.
  • ARS Pharmaceuticals' Accumulated Expenses' 5-year high stood at $11.7 million during FY2021, with a 5-year trough of $2.3 million in FY2024.
  • For the 1-year period, ARS Pharmaceuticals' Accumulated Expenses averaged around $2.3 million, with its median value being $2.3 million (2024).